Conference Paper: High efficacy of high intensity focused ultrasound without transarterial embolization for hepatocellular carcinoma

File Download

re01.htm

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Diagnostic Radiology: Conference papers
- Surgery: Conference papers

Title	High efficacy of high intensity focused ultrasound without transarterial embolization for hepatocellular carcinoma
Authors	Ng, KKC Poon, RTP Cheung, TT Chu, FSK Tso, WK Fan, ST
Issue Date	2009
Publisher	International Liver Cancer Association.
Citation	The 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123 [How to Cite?]
Abstract	BACKGROUND: High-intensity focused ultrasound (HIFU) is a new non-invasive treatment modality for unresectable hepatocellular carcinoma (HCC). Transarterial embolization (TAE) before HIFU has been used to increase the efficacy of ablation, but there are disadvantages associated with this approach. OBJECTIVES: This study aims to evaluate the outcome of patients with HCC after HIFU with and without pre-treatment TAE. METHODS: From October 2006 to April 2008, HIFU was performed in 41 patients with unresectable HCC. Twenty-one patients received TAE two weeks before HIFU in the initial phase of study (period 1), whereas 20 patients underwent HIFU alone in the latter phase of study (period 2). Treatment efficacy was compared between two groups. RESULTS: There were no significant differences between two groups in patient demographic and clinicopathologic parameters. The median size of largest tumor was similar in period 1 and period 2 (2.7cm versus 2.1cm). Both groups received similar amount of energy from HIFU. The overall mortality rate was 2.4% and the overall complication rate was 12.1%. The complete tumor ablation rate in period 2 was significantly higher than that in period 1 (95% vs. 65%, P = 0.044). Taking into consideration of the total number of ablated tumor nodules, the complete ablation rate in period 2 was 96%, which was significantly higher than that in period 1 (68%). (P = 0.020) The overall recurrence rate was 44.4%. There was no significant difference in recurrence rate between patients in period 1 (56.2%) and period 2 (35%) (P = 0.501). Short-term survival outcome between the two groups (period 1 vs. period 2) were similar (86.5% vs. 79% at 1 year, P = 0.074). CONCLUSION: HIFU without pre-treatment TAE is more effective than combined treatment approach in terms of high complete tumor ablation rate. HIFU treatment is a promising treatment modality for patients with unresectable HCC.
Description	Poster Presentation: abstract no. P-123

DC Field	Value
dc.contributor.author	Ng, KKC
dc.contributor.author	Poon, RTP
dc.contributor.author	Cheung, TT
dc.contributor.author	Chu, FSK
dc.contributor.author	Tso, WK
dc.contributor.author	Fan, ST
dc.date.accessioned	2010-10-31T12:57:06Z
dc.date.available	2010-10-31T12:57:06Z
dc.date.issued	2009
dc.description.abstract	BACKGROUND: High-intensity focused ultrasound (HIFU) is a new non-invasive treatment modality for unresectable hepatocellular carcinoma (HCC). Transarterial embolization (TAE) before HIFU has been used to increase the efficacy of ablation, but there are disadvantages associated with this approach. OBJECTIVES: This study aims to evaluate the outcome of patients with HCC after HIFU with and without pre-treatment TAE. METHODS: From October 2006 to April 2008, HIFU was performed in 41 patients with unresectable HCC. Twenty-one patients received TAE two weeks before HIFU in the initial phase of study (period 1), whereas 20 patients underwent HIFU alone in the latter phase of study (period 2). Treatment efficacy was compared between two groups. RESULTS: There were no significant differences between two groups in patient demographic and clinicopathologic parameters. The median size of largest tumor was similar in period 1 and period 2 (2.7cm versus 2.1cm). Both groups received similar amount of energy from HIFU. The overall mortality rate was 2.4% and the overall complication rate was 12.1%. The complete tumor ablation rate in period 2 was significantly higher than that in period 1 (95% vs. 65%, P = 0.044). Taking into consideration of the total number of ablated tumor nodules, the complete ablation rate in period 2 was 96%, which was significantly higher than that in period 1 (68%). (P = 0.020) The overall recurrence rate was 44.4%. There was no significant difference in recurrence rate between patients in period 1 (56.2%) and period 2 (35%) (P = 0.501). Short-term survival outcome between the two groups (period 1 vs. period 2) were similar (86.5% vs. 79% at 1 year, P = 0.074). CONCLUSION: HIFU without pre-treatment TAE is more effective than combined treatment approach in terms of high complete tumor ablation rate. HIFU treatment is a promising treatment modality for patients with unresectable HCC.
dc.description.nature	link_to_OA_fulltext
dc.description	Poster Presentation: abstract no. P-123
dc.description.other	The 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123
dc.identifier.citation	The 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123 [How to Cite?]
dc.identifier.epage	48
dc.identifier.hkuros	180773
dc.identifier.spage	48
dc.identifier.uri	http://hdl.handle.net/10722/126936
dc.language	eng
dc.publisher	International Liver Cancer Association.
dc.relation.ispartof	Abstracts Book of the Annual Conference of the International Liver Cancer Association, ILCA 2009
dc.title	High efficacy of high intensity focused ultrasound without transarterial embolization for hepatocellular carcinoma
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Ng, KKC</contributor.author><contributor.author>Poon, RTP</contributor.author><contributor.author>Cheung, TT</contributor.author><contributor.author>Chu, FSK</contributor.author><contributor.author>Tso, WK</contributor.author><contributor.author>Fan, ST</contributor.author><date.accessioned>2010-10-31T12:57:06Z</date.accessioned><date.available>2010-10-31T12:57:06Z</date.available><date.issued>2009</date.issued><identifier.citation>The 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123</identifier.citation><identifier.uri>http://hdl.handle.net/10722/126936</identifier.uri><description>Poster Presentation: abstract no. P-123</description><description.abstract>BACKGROUND: High-intensity focused ultrasound (HIFU) is a new non-invasive treatment modality for unresectable hepatocellular carcinoma (HCC). Transarterial embolization (TAE) before HIFU has been used to increase the efficacy of ablation, but there are disadvantages associated with this approach. OBJECTIVES: This study aims to evaluate the outcome of patients with HCC after HIFU with and without pre-treatment TAE. METHODS: From October 2006 to April 2008, HIFU was performed in 41 patients with unresectable HCC. Twenty-one patients received TAE two weeks before HIFU in the initial phase of study (period 1), whereas 20 patients underwent HIFU alone in the latter phase of study (period 2). Treatment efficacy was compared between two groups. RESULTS: There were no significant differences between two groups in patient demographic and clinicopathologic parameters. The median size of largest tumor was similar in period 1 and period 2 (2.7cm versus 2.1cm). Both groups received similar amount of energy from HIFU. The overall mortality rate was 2.4% and the overall complication rate was 12.1%. The complete tumor ablation rate in period 2 was significantly higher than that in period 1 (95% vs. 65%, P = 0.044). Taking into consideration of the total number of ablated tumor nodules, the complete ablation rate in period 2 was 96%, which was significantly higher than that in period 1 (68%). (P = 0.020) The overall recurrence rate was 44.4%. There was no significant difference in recurrence rate between patients in period 1 (56.2%) and period 2 (35%) (P = 0.501). Short-term survival outcome between the two groups (period 1 vs. period 2) were similar (86.5% vs. 79% at 1 year, P = 0.074). CONCLUSION: HIFU without pre-treatment TAE is more effective than combined treatment approach in terms of high complete tumor ablation rate. HIFU treatment is a promising treatment modality for patients with unresectable HCC.</description.abstract><language>eng</language><publisher>International Liver Cancer Association.</publisher><relation.ispartof>Abstracts Book of the Annual Conference of the International Liver Cancer Association, ILCA 2009</relation.ispartof><title>High efficacy of high intensity focused ultrasound without transarterial embolization for hepatocellular carcinoma</title><type>Conference_Paper</type><description.nature>link_to_OA_fulltext</description.nature><identifier.hkuros>180773</identifier.hkuros><identifier.spage>48</identifier.spage><identifier.epage>48</identifier.epage><description.other>The 3rd Annual Conference of the International Liver Cancer Association (ILCA), Milan, Italy, 4-6 September 2009. In Abstracts Book of the 3rd ILCA, 2009, p. 48, abstract no. P-123</description.other><bitstream.url>http://hub.hku.hk/bitstream/10722/126936/1/re01.htm</bitstream.url></item>